PRRT2 and cancer: Despite these unfavorable results, the fact remains that PKC isozymes constitute attractive therapeutic targets for cancer, and satisfactory clinical results with PKC inhibitors may be obtained when combined with other inhibitors of cancer-related signaling pathways (e.g., TKIs) [7].